BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32538885)

  • 1. Is cell-based therapy more efficacious for people with amyotrophic lateral sclerosis/motor neuron disease than placebo or no treatment? - A Cochrane review summary with commentary.
    Ceravolo MG
    NeuroRehabilitation; 2020; 46(4):613-615. PubMed ID: 32538885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
    Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
    JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
    Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
    Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.
    Dalbello-Haas V; Florence JM; Krivickas LS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005229. PubMed ID: 18425913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease.
    Guo J; Zhou M; Yang M; Zhu C; He L
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008554. PubMed ID: 21901724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.
    Oh KW; Noh MY; Kwon MS; Kim HY; Oh SI; Park J; Kim HJ; Ki CS; Kim SH
    Ann Neurol; 2018 Sep; 84(3):361-373. PubMed ID: 30048006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2012 Dec; 12():CD005225. PubMed ID: 23235621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis.
    Siwek T; Jezierska-Woźniak K; Maksymowicz S; Barczewska M; Sowa M; Badowska W; Maksymowicz W
    Med Sci Monit; 2020 Dec; 26():e927484. PubMed ID: 33301428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
    Abdul Wahid SF; Law ZK; Ismail NA; Azman Ali R; Lai NM
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011742. PubMed ID: 27822919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.
    Baldinger R; Katzberg HD; Weber M
    Cochrane Database Syst Rev; 2012 Apr; (4):CD004157. PubMed ID: 22513921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.
    Berry JD; Cudkowicz ME; Windebank AJ; Staff NP; Owegi M; Nicholson K; McKenna-Yasek D; Levy YS; Abramov N; Kaspi H; Mehra M; Aricha R; Gothelf Y; Brown RH
    Neurology; 2019 Dec; 93(24):e2294-e2305. PubMed ID: 31740545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2001; (4):CD001447. PubMed ID: 11687111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy - a perspective on cell biological mechanisms.
    Tang BL
    Rev Neurosci; 2017 Oct; 28(7):725-738. PubMed ID: 28599400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study.
    Barczewska M; Maksymowicz S; Zdolińska-Malinowska I; Siwek T; Grudniak M
    Stem Cell Rev Rep; 2020 Oct; 16(5):922-932. PubMed ID: 32725316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
    Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study.
    Kim HY; Kim H; Oh KW; Oh SI; Koh SH; Baik W; Noh MY; Kim KS; Kim SH
    Stem Cells; 2014 Oct; 32(10):2724-31. PubMed ID: 24966156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.